Prophylaxis and therapy of diabetes mellitus I with the help of proteolytic enzymes

Abstract

The present invention relates to the use of proteolytic enzymes for the prophylaxis and/or therapy of type I diabetes mellitus. The proteolytic enzymes are preferably used at the prediabetic stage.

1 . Use of at least one proteolytic enzyme for the prophylaxis and/or therapy of type I diabetes mellitus.  
     
     
         2 . Use according to  claim 1 , characterized in that trypsin, chymotrypsin, bromelain or papain or a combination of several of said enzymes is used as the proteolytic enzyme.  
     
     
         3 . Use according to  claim 1  or  2 , characterized in that a flavonoyl glycoside, preferably rutoside, is additionally used.  
     
     
         4 . Use according to at least one of  claims 1  to  3 , characterized in that 20 to 100 mg bromelain, 40 to 120 mg papain and 10 to 50 mg trypsin are used per dose unit.  
     
     
         5 . Use according to one or several of  claims 1  to  4 , characterized in that 90 mg bromelain, 120 mg papain and 100 mg rutoside are used per dose unit.  
     
     
         6 . Use according to one or several of  claims 1  to  4 , characterized in that 90 mg bromelain, 48 mg trypsin and 100 mg rutoside are used per dose unit.  
     
     
         7 . Use according to one or several of  claims 1  to  6 , characterized in that the prophylaxis of type I diabetes mellitus is carried out at the prediabetic stage.